PAMU
CTMX icon

Pictet Asset Management (UK)’s CytomX Therapeutics CTMX Stock Holding History

Pictet Asset Management (UK)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-611,356
Closed -$6.57M – 1022
2019
Q1 		$6.57M Buy
611,356
+5,670
+0.9% +$83.8K 0.01% 642
2018
Q4 		$9.15K Sell
605,686
-11,523
-2% -$171K 0.02% 518
2018
Q3 		$11.4M Buy
617,209
+92,725
+18% +$2.11M 0.02% 532
2018
Q2 		$12M Buy
524,484
+51,535
+11% +$1.32M 0.03% 480
2018
Q1 		$13.5M Sell
472,949
-113,663
-19% -$3.24M 0.03% 451
2017
Q4 		$12.4M Buy
+586,612
New +$12.2M 0.03% 465

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pictet Asset Management (UK)'s CTMX Position: Q2 2019 in Review

Pictet Asset Management (UK) sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 611,356 shares — an estimated $6.57M sold.

Pictet Asset Management (UK) first reported a position in CTMX in Q4 2017 and held it in 6 quarters. The position peaked at $13.5M in Q1 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Pictet Asset Management (UK) reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 611,356 CytomX Therapeutics shares in Q2 2019, an estimated $6.57M.
  • Pictet Asset Management (UK) first reported a position in CytomX Therapeutics in Q4 2017 and held it in 6 quarters.
  • Pictet Asset Management (UK)'s CytomX Therapeutics position peaked at $13.5M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2019, filed 13 Aug 2019.